Want to see IRON full AI Analyst Report?
Top Page
Disc Medicine
(NASDAQ:IRON)
Select Model
Select Model
Rating:52Neutral
Price Target:
$74.00
▼(-0.16% Downside)
Action:Reiterated
Date:07/30/26
The score is primarily held back by pre-revenue status alongside accelerating losses and heavy negative free cash flow (financial performance). A strong, low-debt balance sheet and financing flexibility from recent debt-capacity expansion provide meaningful offset, while technicals are mixed and valuation is pressured by the negative P/E and lack of dividend yield.
Positive Factors
Low leverage / strong equity base
Disc Medicine’s very low debt relative to substantial shareholders’ equity provides durable financial flexibility to fund lengthy clinical programs and negotiate partnerships. A strong equity cushion reduces immediate solvency risk and supports strategic optionality over the next 6–24 months as trials progress.
Negative Factors
Pre-revenue with accelerating losses
Being pre-revenue, the company lacks operating income to offset rising R&D and G&A spend. Rapidly widening net losses mean returns are negative and operating leverage is absent; absent clear commercial milestones, losses can continue to erode capital and increase financing frequency over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / strong equity base
Disc Medicine’s very low debt relative to substantial shareholders’ equity provides durable financial flexibility to fund lengthy clinical programs and negotiate partnerships. A strong equity cushion reduces immediate solvency risk and supports strategic optionality over the next 6–24 months as trials progress.
Read all positive factors
Disc Medicine (IRON) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.09B
Dividend YieldN/A
Average Volume (3M)666.06K
Price to Earnings (P/E)―
Beta (1Y)1.52
Revenue GrowthN/A
EPS Growth-47.00%
CountryUS
Employees165
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-6.60
Shares Outstanding38,392,845
10 Day Avg. Volume352,719
30 Day Avg. Volume666,056
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)3.79
Price to Sales (P/S)0.00
P/FCF Ratio-15.46
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$100.67Price Target Upside35.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-6.6
Revenue Forecast (FY)N/A
Disc Medicine Business Overview & Revenue Model
Company Description
Based in Watertown, Massachusetts, Disc Medicine, Inc. operates as a clinical-stage biotechnology company. Its core mission involves the discovery, development, and commercialization of novel therapeutic solutions for individuals suffering from se...
How the Company Makes Money
Disc Medicine is a clinical-stage biotech and, as such, does not typically generate recurring revenue from marketed products; its cash inflows generally come from financing and, where applicable, business development arrangements. The company’s pr...
Disc Medicine Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
78
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -241.67M | -207.94M | -108.27M | -76.23M | -46.74M | -33.78M |
| Net Income | -245.89M | -212.18M | -109.36M | -76.43M | -46.83M | -35.97M |
Balance Sheet | ||||||
| Total Assets | 735.07M | 806.88M | 496.77M | 368.00M | 200.21M | 92.41M |
| Cash, Cash Equivalents and Short-Term Investments | 717.75M | 791.15M | 489.88M | 360.38M | 194.61M | 88.04M |
| Total Debt | 60.86M | 1.86M | 30.00M | 2.10M | 1.33M | 7.06M |
| Total Liabilities | 90.91M | 67.05M | 53.19M | 22.88M | 23.61M | 156.61M |
| Stockholders Equity | 644.16M | 739.83M | 443.59M | 345.12M | 176.60M | -64.20M |
Cash Flow | ||||||
| Free Cash Flow | -197.58M | -181.33M | -94.43M | -73.55M | -42.40M | -27.60M |
| Operating Cash Flow | -197.54M | -180.39M | -93.93M | -73.46M | -42.25M | -27.53M |
| Investing Cash Flow | -93.42M | -394.30M | -292.33M | -89.00K | -151.00K | -68.00K |
| Financing Cash Flow | 262.30M | 473.41M | 218.31M | 239.38M | 148.98M | 89.93M |
Disc Medicine Technical Analysis
Positive
74.12
Price Trends
74.25
Positive
70.70
Positive
74.59
Positive
Market Momentum
1.55
Negative
59.23
Neutral
75.72
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IRON, the sentiment is Positive. The current price of 74.12 is below the 20-day moving average (MA) of 76.88, below the 50-day MA of 74.25, and below the 200-day MA of 74.59, indicating a bullish trend. The MACD of 1.55 indicates Negative momentum. The RSI at 59.23 is Neutral, neither overbought nor oversold. The STOCH value of 75.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IRON.
Disc Medicine Risk Analysis
Disc Medicine disclosed 83 risk factors in its most recent earnings report. Disc Medicine reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Disc Medicine Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $3.30B | 116.98 | 15.05% | ― | 76.11% | ― | |
61 Neutral | $3.07B | -63.19 | -13.53% | ― | 105.17% | 53.58% | |
58 Neutral | $5.86B | -136.51 | -55.79% | ― | 77.12% | 64.40% | |
54 Neutral | $2.04B | -4.77 | -35.67% | ― | 140.58% | -161.11% | |
52 Neutral | $3.09B | -12.12 | -37.17% | ― | ― | -47.00% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $1.76B | -3.16 | -50.41% | ― | -15.08% | 41.98% |
* Healthcare Sector Average
IRON
Disc Medicine
78.84
18.98
31.71%
AGIO
Agios Pharma
33.56
-3.45
-9.32%
TVTX
Travere Therapeutics
62.14
43.32
230.18%
ARQT
Arcutis Biotherapeutics
26.19
9.30
55.06%
TARS
Tarsus Pharmaceuticals
69.20
14.99
27.65%
RXRX
Recursion Pharmaceuticals
3.16
-2.61
-45.23%
Disc Medicine Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Disc Medicine Amends Loan Agreement, Expands Debt Capacity
Positive
Jun 30, 2026
On June 25, 2026, Disc Medicine, Inc. amended its existing Loan and Security Agreement with Hercules Capital, Inc. to extend the periods during which it can draw future debt financing tranches. Under the amendment, the company agreed to immediatel...
Executive/Board ChangesShareholder Meetings
Disc Medicine Stockholders Approve Governance and Executive Pay
Positive
Jun 24, 2026
At its annual meeting of stockholders held on June 18, 2026, Disc Medicine, Inc. reported the election of three Class III directors, Donald Nicholson, Ph.D., John Quisel, J.D., Ph.D., and William White, M.P.P., J.D., to serve three-year terms endi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.